Compare Inovio Pharmaceuticals Inc (INO) vs Viatris Inc (VTRS) Price & Performance

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.

The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.

Viatris (VTRS) trades at $17.25, down 1.65% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $3.51 billion for 2025, though recent quarters have consistently beaten EPS estimates. Revenue remains stable around $14.3 billion, with a dividend of $0.12 declared for September 2026. The balance sheet shows a debt-to-asset ratio of 38.74% for 2025, with positive operating cash flow of $2.32 billion.

The outlook is mixed: analyst consensus is a Buy with a $22.17 price target, indicating 28% upside, supported by strong cash generation and pipeline progress. However, persistent net losses, high P/E ratio of 236.2, and competitive pressures in the generics market pose significant risks. Investor sentiment is cautiously optimistic, driven by earnings beats and strategic approvals like WAKIX in Japan.